{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:49:58Z","timestamp":1786992598099,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012295","name":"NIHR Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["777377"],"award-info":[{"award-number":["777377"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jhepr.2021.100411","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T12:31:57Z","timestamp":1637584317000},"page":"100411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-6970","authenticated-orcid":false,"given":"Kate","family":"Hallsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Hauvespre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eid","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3901-7390","authenticated-orcid":false,"given":"Victoria","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100411_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib3","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100411_bib4","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study","volume":"2","author":"O\u2019Hara","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2021.100411_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A\u00a0cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100411_bib7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/tbm\/ibz080","article-title":"Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study","volume":"10","author":"Hallsworth","year":"2020","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.jhepr.2021.100411_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s10620-016-4083-8","article-title":"Medical and surgical treatment options for nonalcoholic steatohepatitis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100411_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.485","article-title":"A\u00a0structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)","volume":"7","author":"Povsic","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jhepr.2021.100411_bib10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s10620-015-3540-0","article-title":"Reversing advanced hepatic fibrosis in NASH: clearly possible, but widely at hand?","volume":"60","author":"Caldwell","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100411_bib11","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1007\/s11606-019-05340-9","article-title":"Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study","volume":"34","author":"Cleveland","year":"2019","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jhepr.2021.100411_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100411_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jclinpath-2013-201620","article-title":"Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification","volume":"66","author":"Dyson","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jhepr.2021.100411_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.11622\/smedj.2018145","article-title":"A\u00a0practical clinical approach to liver fibrosis","volume":"59","author":"Kumar","year":"2018","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jhepr.2021.100411_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100411_bib16","first-page":"661","article-title":"Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD","volume":"8","author":"Alkhouri","year":"2012","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"10.1016\/j.jhepr.2021.100411_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","article-title":"Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations","volume":"51","author":"Cast\u00e9ra","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100411_bib18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1155\/2014\/675409","article-title":"Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a\u00a0nationwide, Canadian survey","volume":"28","author":"Sebastiani","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib20","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.3748\/wjg.v26.i25.3528","article-title":"Management of nonalcoholic fatty liver disease in the Middle East","volume":"26","author":"Sanai","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100411_bib21","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes \u2013 a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jhepr.2021.100411_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2021.100411_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jhepr.2021.100411_bib24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100411_bib25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2021.100411_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality\u00a0in\u00a0NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100411_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with non-alcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100411_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/hep.30886","article-title":"Noninvasive tests of liver fibrosis and their combination in nonalcoholic fatty liver disease: from selected patients to real-life populations","volume":"70","author":"Boursier","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100411_bib32","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.cgh.2017.06.011","article-title":"Lifestyle behavior change in patients with nonalcoholic fatty liver disease: a qualitative study of clinical practice","volume":"15","author":"Avery","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib33","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jhepr.2021.100411_bib34","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib36","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1517\/14740338.2014.937422","article-title":"Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?","volume":"13","author":"Keen","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhepr.2021.100411_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2016.07.009","article-title":"Statin intolerance: a literature review and management strategies","volume":"59","author":"Saxon","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jhepr.2021.100411_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-020-0315-7","article-title":"NAFLD \u2014 sounding the alarm on a silent epidemic","volume":"17","author":"Lazarus","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100411_bib39","unstructured":"Plucker E, Wait S. The Health Policy Partnership. Creating a policy narative around NASH in Europe and the Middle East. Available at: https:\/\/www.healthpolicypartnership.com\/app\/uploads\/Creating-a-policy-narrative-around-NASH-in-Europe-and-the-Middle-East.pdf (accessed December 1, 2021)."}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:26:54Z","timestamp":1762900014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921001877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2589555921001877"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100411","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100411"}}